YZYing-Wen Zhang

Ying-Wen Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ying-Wen Zhang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Xiu-Ping Wang

    Department of Integrated Chinese and Western Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China

    4 shared publications
  • Yi Li

    Department of Medical Oncology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

    4 shared publications
  • Chao-Chao Yu

    Affiliation Department of Rehabilitation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    3 shared publications
  • Chaoyan Wu

    Deparment of Traditional Chinese Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

    3 shared publications
  • Wang Ai

    Department of Nephropathy, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, Hubei, China

    3 shared publications
  • Xiuping Wang

    Deparment of Traditional Chinese Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

    3 shared publications

Latest Publications

    • 1 January 2026
      • Vol. 56  (1) , 42-50

    STCB Inhibits HepG2 Cell Proliferation by Regulating Ras Signaling and Autophagy.

    by Hao-Liang Ke, Zhen Zhou, Wang Ai, Lu Peng, Xiu-Ping Wang, Ying-Wen Zhang

    The role of traditional Chinese medicine in cancer treatment is becoming increasingly pivotal. Tupistra chinensis Baker (STCB), a member of the Lily family, is an herbal plant with antipyretic and detoxifying properties. It has also been used to alleviate abdominal distension. Previous studies have shown that saponin extracted from STCB inhibits proliferation of hepatic carcinoma (HCC) cells. The present study aimed to explore the mechanisms implicated in the regulation of HCC progression by STCB. The impact of STCB on HepG2 hepatoblastoma cell proliferation in vitro was evaluated using Cell Counting Kit-8 assay. The levels of Ras signaling-related and autophagy-related proteins in cancer cells and tumor tissues were determined using Western blot, immunohistochemistry, and immunofluorescence assays. STCB significantly inhibited cell growth similar to Salirasib in vitro. STCB combined with Salirasib resulted in a higher inhibition rate of HepG2 cell growth. STCB treatment also suppressed Ras expression and phosphorylation of its downstream proteins. STCB treatment also upregulated levels of autophagy-related proteins. In mouse xenograft models, STCB impeded growth of subcutaneously transplanted hepatic tumors as well as inhibited Ras signaling, similar to cisplatin treatment. STCB significantly inhibited HepG2 cell proliferation by downregulating Ras signaling-related proteins and inducing autophagy.

  • Open Access

    LncPRESS1 promotes the progression and cisplatin resistance of breast cancer through upregulation of ENO1 and activation of glycolysis

    by Longzhu Ke, Wei Gao, Yuanxiu Leng, Jie Chen, Hong Chen, Shangshang Li, Yingwen Zhang, Li Luo

    Overexpression or downregulation of long noncoding RNA (lncRNA) plays an essential role in the progression and chemotherapy-resistant of breast cancer (BRCA). LncPRESS1 is a lncRNA regulated by p53, suggesting its potential in participating in carcinogenesis. However, few evidences reported the role of LncPRESS1 in tumor development. The clinical significance of LncPRESS1 was explored in BRCA and normal samples derived from the patients. Overexpression and knockdown of LncPRESS1 were performed by lentivirus. CCK-8 and colony formation were conducted to examined the proliferation ability of BRCA cells. Apoptosis was measured by PI/Annexin V staining and the activity of caspase 3/7. Xenografted tumorigenesis in nude mice was applied to explore the role of LncPRESS1 on BRCA progression and cisplatin response. RT-qPCR was used to detect the mRNA level, while immunoblotting was applied to check the protein level. In this study, we identified that LncPRESS1 was significantly upregulated in BRCA tissues as compared with normal tissues, and in the cancer tissues with late stage or node metastasis. LncPRESS1 abundance was not changed among the patients based on the expression of estrogen receptor, progesterone receptor, or epidermal growth factor 2. In vitro, LncPRESS1 suppressed the apoptosis, while enhanced the proliferation and cisplatin resistance in BRCA cells. Upregulation of LncPRESS1 was also observed in the patients who did not response to cisplatin treatment. In vivo, knockdown of LncPRESS1 suppressed the tumorigenesis of BRCA cells and enhanced the effectiveness of cisplatin. Mechanistically, LncPRESS1 activated glycolysis via upregulation of ENO1. Overexpression of LncPRESS1 dictated the sensitivity of BRCA cells to ENO1 inhibitor, ENOblock. Importantly, treatment of ENOblock reduced the resistance of cisplatin in BRCA cells with overexpression of LncPRESS1. In summary, we demonstrated that LncPRESS1 facilitated BRCA progression and cisplatin resistance via activation of ENO1-mediated glycolysis. Combination of ENO1 inhibitor and cisplatin was a promising therapeutic stragtegy for BRCA patients with overexpression of LncPRESS1.

  • Open Access

    Yiai Fuzheng decoction inhibits triple-negative breast cancer by remodeling the immune microenvironment

    by Chaochao Yu, Chengqian Jia, Guopeng Chen, Yi Li, Yixin Liu, Yingwen Zhang

    Objective: This study aimed to examine the potential anticancer properties of Yiai Fuzheng decoction (YFD), along with its mechanism of action against triple-negative breast cancer (TNBC).Methods: A TNBC mouse model was established by inoculating 4T1 cells into the 4th mammary fat pad. Micropositron emission tomography (micro-PET), hematoxylin and eosin (HE) staining, immunohistochemistry, immunofluorescence assays, flow cytometry, and western blotting were used to assess the therapeutic effects of YFD. The components of YFD were identified via UHPLC-Q/Orbitrap MS. Nontargeted metabolomic analysis was performed to identify changes in tumor metabolites via gas chromatography-time-of-flight mass spectrometry (GC-TOF/MS). The Illumina sequencing platform was used to identify differentially expressed genes in the tumors.Results: A total of 20 bioactive components of YFD were screened and identified. We found that YFD treatment resulted in a substantial increase in CD4+ and CD8+ T cells, a reduction in myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), and an increase in the M1/M2 ratio of TAMs in tumors. These changes create a tumor-suppressive microenvironment that inhibits tumor growth and metastasis in TNBC mice. YFD can affect various immune regulatory pathways, such as inactivation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1 and 2 (MEK/ERK1/2) pathway. Additionally, metabolomic analysis suggested that YFD could reprogram several altered metabolic pathways, including the urea cycle; metabolism of arginine and proline; pyruvate; the Warburg effect; D-arginine; and D-ornithine, glutamate, glycine, serine, and tryptophan, to suppress cancer progression.Conclusion: Our findings provide preclinical evidence that supports the application of YFD in TNBC treatment.


  • Open Access

    Network pharmacology and experimental verification to decode the action of Qing Fei Hua Xian Decotion against pulmonary fibrosis

    by Hao-Liang Ke, Rui-Jie Li, Chao-Chao Yu, Xiu-Ping Wang, Chao-Yan Wu, Ying-Wen Zhang

    Background: Pulmonary fibrosis (PF) is a common interstitial pneumonia disease, also occurred in post-COVID-19 survivors. The mechanism underlying the anti-PF effect of Qing Fei Hua Xian Decotion (QFHXD), a traditional Chinese medicine formula applied for treating PF in COVID-19 survivors, is unclear. This study aimed to uncover the mechanisms related to the anti-PF effect of QFHXD through analysis of network pharmacology and experimental verification. Methods: The candidate chemical compounds of QFHXD and its putative targets for treating PF were achieved from public databases, thereby we established the corresponding “herb-compound-target” network of QFHXD. The protein–protein interaction network of potential targets was also constructed to screen the core targets. Furthermore, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were used to predict targets, and pathways, then validated by in vivo experiments. Results: A total of 188 active compounds in QFHXD and 50 target genes were identified from databases. The key therapeutic targets of QFHXD, such as PI3K/Akt, IL-6, TNF, IL-1β, STAT3, MMP-9, and TGF-β1 were identified by KEGG and GO analysis. Anti-PF effects of QFHXD (in a dose-dependent manner) and prednisone were confirmed by HE, Masson staining, and Sirius red staining as well as in vivo Micro-CT and immunohistochemical analysis in a rat model of bleomycin-induced PF. Besides, QFXHD remarkably inhibits the activity of PI3K/Akt/NF-κB and TGF-β1/Smad2/3. Conclusions: QFXHD significantly attenuated bleomycin-induced PF via inhibiting inflammation and epithelial-mesenchymal transition. PI3K/Akt/NF-κB and TGF-β1/Smad2/3 pathways might be the potential therapeutic effects of QFHXD for treating PF.


  • Qing Fei Hua Xian Decoction ameliorates bleomycin-induced pulmonary fibrosis by suppressing oxidative stress through balancing ACE-AngII-AT1R/ACE2-Ang-(1-7)-Mas axis

    by Rui-jie Li, Chao-yan Wu, Hao-liang Ke, Xiu-ping Wang, Ying-wen Zhang

    Objective(s): We aimed to investigate the preventative effect of Qing Fei Hua Xian Decoction (QFHXD) against pulmonary fibrosis (PF) and its potential mechanisms. Materials and Methods: Bleomycin (BLM)-induced rats were respectively treated with 413.3, 826.6, and 1239.9 mg/kg of QFHXD and prednisone for 28 days. The lung tissues of rats were collected on day 28 for histological and western blotting analysis. Results: QFHXD significantly reduced alveolus inflammation, collagen accumulation, and fibrosis deposition in BLM-induced PF rats (P<0.05). Collagen I and III, vimentin, and alpha-smooth muscle actin(alpha-SMA) expression levels were likewise decreased in PF rats treated with QFHXD (P<0.05). Additionally, QFHXD increased the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) while decreasing NADPH oxidase 4 (NOX4) expression (P<0.05). Furthermore, QFHXD suppressed the PF progression by down-regulating Angiotensin-Converting Enzyme (ACE) -Angiotensin II (AngII) -Angiotensin II Type 1 Receptor (AT1R) axis (P<0.01) and up-regulating Angiotensin-Converting Enzyme 2 (ACE2) -Angiotensin-(1-7) (Ang-(1-7)) -Mas axis (P<0.05). Conclusion: QFHXD suppressed inflammatory infiltration and PF brought on by BLM in lung tissues through reducing oxidative stress by maintaining the equilibrium of ACE-AngII-AT1R and ACE2Ang-(1-7) -Mas axes. This study may provide a novel clinical therapy option for PF.


  • Open Access

    Author Correction: Compound Opening Arrow Mixture exerts anti-tumor effects in a mouse model of breast cancer

    by Zhen Zhou, Yanfang Peng, Wang Ai, Qi Li, Taisheng Ye, Chaoyan Wu, Haoliang Ke, Xiuping Wang, Yingwen Zhang

  • Bioactive constituents of animal-derived traditional Chinese medicinal materials for breast cancer: opportunities and challenges

    by Chaochao Yu, Yi Li, Guopeng Chen, Chaoyan Wu, Xiuping Wang, Yingwen Zhang

    Breast cancer is globally the most common invasive cancer in women and remains one of the leading causes of cancer-related deaths. Surgery, radiotherapy, c


  • Open Access

    Investigation of Anti-Epithelial-Mesenchymal Transition and Anti-Inflammation effects of Qing Fei Hua Xian Decotion on Pulmonary Fibrosis via Network Pharmacology and Experimental Verification

    by Chao-Chao Yu, Rui-Jie Li, Xiao-Fei Wang, Chao-Yan Wu, Yan-Fang Peng, Xiu-Ping Wang, Wei Chen, Lian-Guo Ruan, Ying-Wen Zhang

    Background Pulmonary fibrosis (PF) is a common interstitial pneumonia disease, also occurred in post-COVID-19 survivors. The mechanism underlying the anti-PF effect of Qing Fei Hua Xian Decotion (QFHXD), a traditional Chinese medicine formula applied for treating PF in COVID-19 survivors, is unclear. This study aimed to uncover the mechanisms related to the anti-PF effect of QFHXD through analysis of network pharmacology and experimental verification. Methods The candidate chemical compounds of QFHXD and its putative targets for treating PF were achieved from public databases, thereby we established the corresponding “herb- compound -target” network of QFHXD. Moreover, The protein–protein interaction (PPI) network of potential targets was also constructed to screen the core targets. Furthermore, Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were used to predict targets, and pathways, then validated by in vivo experiments. Results A total of 188 active compounds in QFHXD and 50 target genes were identified from databases. The key therapeutic targets of QFHXD, such as PI3K/Akt, IL-6, TNF, IL-1β, STAT3, MMP-9, and TGF-β1 were identified by KEGG and GO analysis. Anti-PF effects of QFHXD (in a dose-dependent manner) and prednisone were confirmed by HE, Masson staining, and Sirius red staining as well as in vivo Micro-CT and immunohistochemical analysis in a rat model of bleomycin-induced PF. Besides, QFXHD remarkably inhibits the activity of PI3K/Akt/NF-κB and TGF‑β1/Smad2/3. Conclusion QFXHD significantly attenuated bleomycin-induced PF via inhibiting inflammation and EMT. PI3K/Akt/NF-κB and TGF‑β1/Smad2/3 pathways might be the potential therapeutic effects of QFHXD for treating PF.

  • Open Access

    Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions

    by Chao-Chao Yu, Yi Li, Zhao-Jun Cheng, Xi Wang, Wei Mao, Ying-Wen Zhang

    Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, such as hypercalcemia, renal failure, anemia, and bone lesions. Despite improvement in the survival of MM patients with use of myeloma-targeted and immunomodulatory therapies, MM remains an incurable disease. Moreover, patients with relapsed or refractory MM show poor survival outcomes. In recent years, there has been a growing interest in the use of traditional Chinese medicinal materials (TCMMs) for management of a wide spectrum of diseases. The bioactive ingredients derived from TCMMs hold great potential for the development of anticancer drugs. Here we summarize the evidence of the pharmacological effects of the active components in TCMMs on MM, including curcumin, resveratrol, baicalein, berberine, bufalin, cinobufagin, gambogic acid, ginsenoside, icariin, daidzin, formononetin, polysaccharides extracts from Hedyotis difus, and scutellarein. Available evidence indicates that the anti-MM effects of these bioactive ingredients are mediated via regulation of proliferation, apoptosis, autophagy, cell cycle, osteogenic differentiation, and drug resistance. In the future, the underlying mechanisms of the anti-MM effects of these components should be further investigated. Large-scale and well-designed clinical trials are also required to validate the efficacy of these bioactive constituents for MM.


  • Open Access

    Neuroprotective Mechanisms of Puerarin in Central Nervous System Diseases: Update

    by Chao-Chao Yu, Yan-Jun Du, Jin Li, Yi Li, Li Wang, Li-Hong Kong, Ying-Wen Zhang

    Due to global population aging and modern lifestyle changes, the incidence of central nervous system (CNS) disorders, such as neurodegenerative diseases, neuropsychiatric disorders, and cerebrovascular diseases, is increasing and has become a major public health challenge. Current medications commonly used in the clinic are far from satisfactory and may cause serious side effects. Therefore, the identification of novel drugs for the effective management of CNS diseases is very urgent. Puerarin, a highly bioactive ingredient isolated from Pueraria lobata, is known to possess a broad spectrum of pharmacological properties including anti-diabetic, anti-inflammatory, anti-antioxidant, neuroprotective, and cardioprotective features. However, its clinical application is limited due to its poor water solubility. Since puerarin has demonstrated a wide range of neuroprotective functions in various CNS diseases, such as Alzheimer’s disease, Parkinson’s disease, cerebral ischemia, depression, and spinal cord injury, it has been attracting increasingly intense attention worldwide. In this review, we intend to extensively summarize the research progress on neuroprotective mechanisms of puerarin in recent years and discuss the future directions of its application in CNS disease treatment.